Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$41.7K | -$80.9M | -$146M |
| Net income | -$41.7K | -$74.3M | -$134M |
| EPS (diluted) | — | -$5,756.41 | -$4.30 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | — | -$55.0M | -$114M |
| Capital expenditures | — | $49.0K | $606K |
| Free cash flow | — | -$55.1M | -$115M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $250K | $30.9M | $374M |
| Total assets | $333K | $164M | $448M |
| Total liabilities | $396K | $19.6M | $37.3M |
| Shareholders' equity | -$116M | -$179M | $411M |
| Retained earnings | -$88.6K | -$223M | -$357M |
| Shares (wtd avg diluted) | — | 12.9B | 31.1M |
Every figure is extracted from BridgeBio Oncology Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.